Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mimedx (MDXG) EPS (Weighted Average and Diluted) (2016 - 2025)

Historic EPS (Weighted Average and Diluted) for Mimedx (MDXG) over the last 16 years, with Q3 2025 value amounting to $0.11.

  • Mimedx's EPS (Weighted Average and Diluted) rose 12000.0% to $0.11 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.27, marking a year-over-year decrease of 5263.16%. This contributed to the annual value of $0.28 for FY2024, which is 3447.15% down from last year.
  • Mimedx's EPS (Weighted Average and Diluted) amounted to $0.11 in Q3 2025, which was up 12000.0% from $0.06 recorded in Q2 2025.
  • Mimedx's EPS (Weighted Average and Diluted)'s 5-year high stood at $0.34 during Q4 2023, with a 5-year trough of -$0.11 in Q1 2022.
  • Moreover, its 5-year median value for EPS (Weighted Average and Diluted) was $0.05 (2024), whereas its average is $0.02.
  • As far as peak fluctuations go, Mimedx's EPS (Weighted Average and Diluted) crashed by 26666.67% in 2022, and later soared by 180000.0% in 2023.
  • Mimedx's EPS (Weighted Average and Diluted) (Quarter) stood at -$0.02 in 2021, then changed by 0.0% to -$0.02 in 2022, then soared by 1800.0% to $0.34 in 2023, then crashed by 85.32% to $0.05 in 2024, then soared by 120.43% to $0.11 in 2025.
  • Its EPS (Weighted Average and Diluted) stands at $0.11 for Q3 2025, versus $0.06 for Q2 2025 and $0.05 for Q1 2025.